Last reviewed 2026-04-23 · How we verify

E7090

E7090 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).

E7090 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.

At a glance

Mechanism of action

By inhibiting SGLT2, E7090 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating diabetes.

Approved indications

• Type 2 diabetes

Common side effects

• Increased risk of diabetic ketoacidosis

Key clinical trials

• A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer (PHASE1)
• A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion (PHASE2)
• Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants (PHASE1)
• Phase 1 Study of E7090 in Subjects With Solid Tumor (PHASE1)
• NCCH2006/MK010 Trial (FORTUNE Trial) (PHASE2)
• A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants (PHASE1)
• A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.